Clinical Study Overview
Published Research on the Use of Image-Guided Superficial Radiation Therapy (Image-Guided SRT) in the Treatment of Nonmelanoma Skin Cancer (NMSC)
See the clinical research supporting the safety and efficacy of surgery-free GentleCure (Image-Guided SRT) in the treatment of basal cell and squamous cell skin cancers.
Yu L, et al. Oncol Ther. 2021;9(1):153-166.
Retrospective chart review (looking back at patients’ medical records) that evaluated the cure rates of 1632 people with 2917 stage 0-II skin cancers who were treated with GentleCure (Image-Guided SRT)
Results showed that GentleCure (Image-Guided SRT) delivered a 99.3% cure rate and should be considered a first-line treatment option for basal cell and squamous cell skin cancers.
Cure rates observed in this initial period of follow-up are similar, and potentially superior with further follow-up, to traditional SRT and surgical options.
Yu L, et al. Discov Oncol. 2022;13(1):129.
Meta analysis (combining information from different studies to find a common pattern) that compared the cure rates from 2 studies of people with NMSC who were treated with Image-Guided SRT with the cure rates from 4 studies of people who were treated with non-image-guided radiotherapies, including electron beam radiation and superficial radiation therapy
Cure rates for people treated with Image-Guided SRT were shown to be statistically superior to the cure rates for those treated with non-image-guided radiotherapies when the studies were compared individually and all together.
US-SRT [Image-Guided SRT] is statistically superior to non–image-guided radiotherapies for NMSC treatment. This modality may represent the future standard of non-surgical treatment for early-stage NMSC.
Yu L, et all. BMC Cancer. 2023;23(1):98.
Logistic regression analysis (a way to understand and predict how different treatments might influence a result or outcome) that compared the cure rates by skin cancer subtype (basal cell, squamous cell, and squamous cell in situ) from 4 studies of people treated with non-image-guided radiotherapies to 1 study of people treated with Image-Guided SRT
When the studies were compared individually and all together, Image-Guided SRT was shown to deliver statistically superior cure rates across basal cell, squamous cell, and squamous cell in situ skin cancers compared with traditional, non-image-guided radiotherapies.
Image guidance with high resolution dermal ultrasound in the form of US-SRT [Image-Guided SRT] is shown to confer a statistically significant advantage in lesion local control over non–image-guided forms of SRT or XRT [electron beam therapy and superficial radiation therapy] in all subtypes of cutaneous epithelial NMSC and should be considered the preferred standard of non-surgical treatment for early-stage cutaneous BCC, SCC, and SCCIS.
Tran A, et al. J Cancer Res Clin Oncol. 2023.
Retrospective chart review (looking back at patients’ medical records) was conducted to evaluate the cure rates of 1243 people with 1899 stage 0-II NMSC (basal cell, squamous cell, and squamous cell in situ) who received treatment with Image-Guided SRT energies ranging from 50 to 100 kV, for a mean of 20.2 fractions, and treatment dose of 5364.4 cGy
After an average of 7.5 weeks of treatment with Image-Guided SRT, 99.7% of people showed no signs of skin cancer in the treated area, and 95% of people continued to show no signs of skin cancer at the 5-year follow-up visit.
Image-Guided SRT has a high safety profile, can achieve superior cosmesis and should be considered first-line for treating early-stage NMSC tumors as cure rates have been shown to be effective in all NMSC on early follow-up…making it a safe, and potentially cost-effective, option for NMSC treatment compared to surgery.